Giancarlo Paoletti

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Corrigendum to "A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma" [Exp Mol Pathol Volume 146, June 2026, 105049].

Corrigendum to "A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma" [Exp Mol Pathol Volume 146, June 2026, 105049].

Journal: Experimental and molecular pathology

Published: May 28, 2026

A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma.

A WNT/β-catenin-associated transcriptional program predicts survival outcomes in patients with hepatocellular carcinoma.

Journal: Experimental and molecular pathology

Published: January 26, 2026

Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study.

Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 13, 2025

Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial.

Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trial.

Journal: ESMO open

Published: January 20, 2025

Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer.

Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer.

Journal: Clinical and translational medicine

Published: September 19, 2020

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.

Journal: Scientific reports

Published: August 22, 2020

Case Report: Ipilimumab-Induced Panhypophysitis: An Infrequent Occurrence and Literature Review.

Case Report: Ipilimumab-Induced Panhypophysitis: An Infrequent Occurrence and Literature Review.

Journal: Frontiers in oncology

Published: July 11, 2020

Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial.

Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial.

Journal: Cancers

Published: February 14, 2020

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.

Journal: Cancer biology & therapy

Published: November 08, 2018

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting.

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting.

Journal: Therapeutic advances in medical oncology

Published: October 16, 2018

Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting.

Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting.

Journal: Oncotarget

Published: January 10, 2017

Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.

Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: July 26, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026